IRVINE, Calif., March 29, 2006 (PRIMEZONE) -- "Antiviral companies are aggressively developing new candidates for the burgeoning health care sector, driven most obviously by the enormous group of Baby Boomers," stated SmallCap Sentinel analyst D.R. Clark. "The first of the Boomers hit sixty years of age on the first of this year. And that's just the beginning of this enormous demographic of Americans heading for their greatest health care need years."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" is available at www.SmallCapSentinel.com and will address a variety of biotech and pharmaceutical related issues for companies including Merck (NYSE:MRK), Pfizer (NYSE:PFE), Glaxosmithkline PLC (NYSE:GSK), and FermaVir Pharmaceuticals, Inc., (OTCBB:FMVR).
FermaVir Pharmaceuticals, Inc. is an emerging biotechnology company positioned for rapid growth by developing important antiviral drugs and other treatments in underserved segments of the pharmaceutical development marketplace. The company's Intellectual Property portfolio includes a number of granted patents and patent applications and a worldwide exclusive license for potential new drug treatments of infectious diseases.
Among FermaVir's lead drug candidates is a novel antiviral compound that has demonstrated powerful inhibitory activity and may have potential therapeutic benefit for the treatment of shingles, also known as herpes zoster. FermaVir's proprietary compound is believed to be approximately 10,000 times more potent than currently approved shingles drug treatments. FermaVir is also developing compounds that could provide the first improved effective treatment in years for Cytomegalovirus (CMV) infection. CMV is a currently incurable viral disease from the herpes family that can threaten eyesight as well as cause severe morbidity and mortality, especially in immunosupressed patients. FermaVir's compounds appear to work by a new mechanism of action from the current drugs on the market today.
A detailed informational report regarding FermaVir Pharmaceuticals, Inc. is available free to the public at the following link: http://www.trilogy-capital.com/fmvr_summary.aspx
Individuals may also register to receive future reports on emergent public companies and sectors at: http://stockupticks.com/register.html
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by FermaVir for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.